Last reviewed · How we verify

CUTISS AG — Portfolio Competitive Intelligence Brief

CUTISS AG pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
denovoSkin(TM) denovoSkin(TM) phase 3 Regenerative medicine Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amarantus BioScience Holdings, Inc. · 1 shared drug class
  2. Massachusetts General Hospital · 1 shared drug class
  3. zhang li · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CUTISS AG:

Cite this brief

Drug Landscape (2026). CUTISS AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cutiss-ag. Accessed 2026-05-15.

Related